Eisai Obtains Rights To Overactive Bladder Agent Uritos In 13 Asian Countries
This article was originally published in PharmAsia News
Executive SummaryJapanese drug maker Kyorin Pharmaceutical signed a licensing agreement with Eisai Sept. 29 giving Eisai exclusive rights to develop and market overactive bladder agent Uritos (imidafenacin) in China, India, Sri Lanka and 10 ASEAN countries
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”